tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
KalVista Pharmaceuticals (KALV)
NASDAQ:KALV
US Market
KALV
KalVista Pharmaceuticals
RESEARCH TOOLSreports

KalVista Pharmaceuticals (KALV) Stock News & Sentiment

Compare
596 Followers
KalVista’s Pediatric HAE Trial for Sebetralstat Reaches Completion, Setting Up a Key Catalyst for KALV
Premium
Company Announcements
KalVista’s Pediatric HAE Trial for Sebetralstat Reaches Completion, Setting Up a Key Catalyst for KALV
6d ago
KALV
Strong Ekterly Launch and Latin America Expansion Underscore Buy Rating on KalVista
Premium
Ratings
Strong Ekterly Launch and Latin America Expansion Underscore Buy Rating on KalVista
21d ago
KALV
KalVista Highlights Strong EKTERLY Launch and Global Uptake
Premium
Company Announcements
KalVista Highlights Strong EKTERLY Launch and Global Uptake
21d ago
8K
KALV
KalVista (Ekterly) Upgraded as 2026 Top Idea: De-Risked Competitive Landscape, Strengthening Launch Trajectory, and Raised $32 Target Support Buy Rating
Premium
Ratings
KalVista (Ekterly) Upgraded as 2026 Top Idea: De-Risked Competitive Landscape, Strengthening Launch Trajectory, and Raised $32 Target Support Buy Rating
23d ago
KALV
Promising Launch of KalVista’s Ekterly Drives Buy Rating Amid Positive Market Dynamics
Premium
Ratings
Promising Launch of KalVista’s Ekterly Drives Buy Rating Amid Positive Market Dynamics
2M ago
KALV
KalVista Pharmaceuticals: Strategic Market Position and Strong Buy Recommendation
Premium
Ratings
KalVista Pharmaceuticals: Strategic Market Position and Strong Buy Recommendation
2M ago
KALV
Positive Outlook for KalVista Pharmaceuticals Amid Competitive Developments and Market Growth Potential
Premium
Ratings
Positive Outlook for KalVista Pharmaceuticals Amid Competitive Developments and Market Growth Potential
2M ago
KALV
More KALV News >

KALV News on the Web

Bank of America Securities Reaffirms Their Buy Rating on KalVista Pharmaceuticals (KALV)
TipRanks News
Bullish
KalVista’s Pediatric HAE Trial for Sebetralstat Reaches Completion, Setting Up a Key Catalyst for KALV
TipRanks News
Bullish
Does KalVista Pharmaceuticals (KALV) Have the Potential to Rally 117.98% as Wall Street Analysts Expect?
Zacks
Bullish
Why KalVista Pharmaceuticals, Inc.’s (KALV) Stock Is Down 5.61%
AAII
Neutral
KalVista Pharmaceuticals (KALV) Gets a Buy from Jefferies
TipRanks News
Bullish
Stifel Nicolaus Sticks to Their Buy Rating for KalVista Pharmaceuticals (KALV)
TipRanks News
Bullish
EKTERLY’s Blockbuster Start: KalVista’s Fourth Quarter Revenue Points to Shifting HAE Treatment Landscape
Market Chameleon
Neutral
KalVista price target raised to $37 from $27 at H.C. Wainwright
TipRanks News
Bullish

News Score - Last 7 Days

Positive
KALV
Sector Average
Media Buzz
This Week2 articles
Weekly Average3.75 articles
News Sentiment
This Week100%
Sector Average74%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is KALV’s Media Buzz Sentiment?
2 articles about KALV were published this week. In an average week, 3.75 articles are published.
    What is KALV’s weekly average amount of articles?
    In an average week, 3.75 articles about KALV are published.
      What is KALV’s News Sentiment?
      100% of articles about KALV were positive this week, compared to its sector average of 74%.
        Healthcare Stocks that are Trending in the News
        CBLControl Bionics Ltd.
        CRDFCardiff Oncology
        KRROKorro Bio
        VREOFVireo Growth
        CHGCFChugai Pharmaceutical Co
        Showing the stocks with the most bullish news sentiment over the past week